Background/aim: This study aimed to analyze EGFR, KRAS, and BRAF mutations in females with micropapillary predominant invasive lung adenocarcinoma and their relationships with immunohistochemical and clinicopathological patterns.
Introduction
Although lung cancer is not the most frequently observed type of cancer, it is the cause of the most cancerrelated deaths in both males and females worldwide (1) . Adenocarcinomas, which have different clinical, radiological, molecular, and pathological properties, are the most commonly seen histological type of lung cancer, and lung adenocarcinomas have a heterogeneous morphology (2) . Micropapillary dominant invasive adenocarcinoma was defined as a new subtype in the most recent classification of lung adenocarcinomas (3) , and diagnosis is associated with poor prognosis and a high grade (4) . Therefore, targeted therapy may represent the best hope in the treatment of this type of tumor. Nowadays, the most popular therapeutic target is the tyrosine kinase receptor, epidermal growth factor receptor (EGFR). Asian, nonsmoking female patients are particularly suitable for this type of treatment. The KRAS and BRAF mutations are nonresponsive to treatment (5) .
Few molecular studies investigating micropapillary lung adenocarcinomas have previously been conducted (6) (7) (8) (9) (10) . Therefore, we studied the EGFR, KRAS, and BRAF gene mutations and their relationships with the immunohistochemical expressions of the EGFR, vascular endothelial growth factor (VEGFR), c-kit, and bcl-2 oncoproteins in women with micropapillary dominant invasive adenocarcinomas.
Materials and methods
This study was approved by the Ethics Committee of Atatürk Chest Diseases and Thoracic Surgery Education and Research Hospital in Ankara, Turkey. A total of 745 patients underwent complete surgical resection of primary lung adenocarcinoma in this hospital between January 2000 and December 2010, and a group of 15 women with micropapillary dominant invasive adenocarcinoma were retrospectively investigated. All specimens were fixed in 10% buffered formaldehyde and embedded in paraffin, and between four and eight slides, including hematoxylin and eosin-stained pleural surfaces, were reviewed. The histological type of the tumor was assigned according to the American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. Micropapillary components consisted of papillary tufts without a fibrovascular core, and the tumor cells were small and cuboidal with minimal nuclear atypia ( Figure 1 ). The smaller components were semiquantitatively recorded using 5% increments (3). The following histopathological factors were evaluated: tumor diameter, necrosis, mitotic count, vascular invasion, perineural invasion, and predominant cell type (hobnail vs. columnar). Vascular and pleural invasion was evaluated using Verhoeff-van Gieson staining, and mucicarmine staining was used to detect cytoplasmic mucin production. Tumor size was measured as the largest diameter of the cut sections of tumor mass, and the pathological stage was determined based on the criteria of the 7th TNM classification of the Union of International Cancer Control (11) .
Clinical data were obtained from the case histories of the patients. These histories were analyzed with regard to age, smoking status, asbestos exposure, biomass history, tumor location, TNM stage, survival data, and chemotherapy.
In order to carry out immunohistochemistry analysis, 6-µm-thick sections were obtained from micropapillary areas of the paraffin block. The antibodies used were as follows: bcl-2 mouse monoclonal antibody clone 124 (Dako, Denmark), VEGF mouse monoclonal antibody clone VG1 (Thermo-Shandon Lab Vision, USA), c-kit oncoprotein polyclonal antibody (Thermo-Shandon Lab Vision), and EGFR mouse monoclonal clone 2-18C9 (Dako). VEGF, c-kit, bcl-2, and EGFR analysis was performed via the immunoperoxidase method, using the avidin-biotin complex (Thermo-Shandon Lab Vision). Positive controls included lymphocytes for bcl-2, angiosarcoma for VEGF, tonsils for c-kit, and squamous cell carcinoma for EGFR. Negative controls included omission of the primary antibody. Sections were deparaffinized with xylene and dehydrated in a graded alcohol and endogenous peroxidase, using 3% hydrogen peroxide. Antigen retrieval was performed using EDTA for VEGF and bcl-2, citrate for c-kit, and proteinase for EGFR. The reaction products were visualized with DAB, and the samples were semiquantitatively evaluated according to the percentage of cytoplasmic staining for bcl-2 and VEGFR and membranous staining for c-kit and EGFR. Immunostaining with all antibodies was evaluated by dividing the staining reactions into four groups according to cytoplasmic staining intensity: 1 = weak, 2 = moderate, 3 = strong, and 4= very strong. Immunostaining quantity was evaluated as the percentage of tumor cells showing cytoplasmic or membranous positivity as follows: 0 = negative, 1 = <25%, 2 = 25%-50%, 3 = 50%-75%, and 4 = >75%. They were then divided into three groups according to their summed scores: 0 = no immunostaining (a score of 0), 1 = weak immunostaining (scores between 1 and 4), and 2 = strong immunostaining (scores between 5 and 8) (12) .
Formalin-fixed paraffin embedded tissue blocks that were made up of more than 50% tumor cells were used for mutation analysis. For each patient, three 10-µmthick sections of a block were used for DNA extraction, and the DNA was prepared from formalin-fixed, paraffinembedded tissues using a DNA FFPE tissue kit (QIAGEN, Valencia, CA, USA). Microarray-based technology was used to carry out the mutational analysis. The system performs automated, allele-specific, primer extension hybridization on a biofilm chip microarray, as well as fluorescence detection and data analysis. This analysis detects 50 EGFR mutations at exons 18, 19, 20, and 21; 19 KRAS mutations at codons 12, 13, and 61; and seven BRAF mutations at codon 13.
Statistical analysis was performed using SPSS 15.0 (SPSS Inc., Chicago, IL, USA) and McNemar's test was used to assess associations between categorical variables. Two-tailed P-values of <0.05 were considered statistically significant.
Results
The clinicopathological features of 15 females (between the ages of 37 and 76 years old; mean: 50; median: 55) with micropapillary dominant invasive adenocarcinoma are summarized in Table 1 . Of the 15 patients, two (13.2%) had a history of smoking, and nine (60%) were younger than 60 years old. Six cases involved asbestos and biomass exposure, and seven tumors were located in the right upper lobe. Tumor diameter ranged from 15 to 100 mm (mean: 44 mm, median: 40 mm). Following resection, disease stages were identified as follows: stage 1A, four patients; stage 1B, three patients; stage 2A, one patient; stage 2B, one patient; stage 3A, three patients; and stage 3B, two patients.
A micropapillary pattern (MPP) was found in 45%-80% of the tumor mass ( Figure 1 ), while secondary minor patterns included a papillary pattern in six (40%) cases, an acinar pattern in five (33.4%) cases, a lepidic pattern in three (20%) cases, and a solid pattern in one (6.6%) case. Cytologically, the tumors revealed a predominant cell type of hobnail in four (26.6%) cases, columnar in nine (60%) cases, and polygonal in two (13.2%) cases. Psammoma bodies were observed in four (27%) cases. Only one case showed a signet ring change (case 7). Table 2 summarizes the mutation analysis and immunohistochemical findings. All cases were positive for VEGF (strongly positive in 11 cases, weakly positive in four cases) and bcl-2 (strongly positive in nine cases, weakly positive in six cases). A total of seven (46.6%) cases were positive for c-kit, and 10 (66.6%) cases were positive for EGFR ( Figures 2-5 ).
Molecular analysis showed that nine (60%) cases had mutations involving EGFR, KRAS, and BRAF; six (40%) cases showed EGFR mutation, including at exon 19 in five cases and at exon 20 in one case; three (20%) cases had KRAS mutation, including at codons 12, 13, and 61. One (6.6%) case had both KRAS (codons 12 and 61) and BRAF (V600E) mutations (case 11). Tables 3 and 4 show the nucleotide changes in EGFR, KRAS, and BRAF in our case studies.
Of the cases showing EGFR mutation, three were positive for c-kit, five were positive for EGFR, and four contained a papillary pattern as a secondary pattern. Of the cases with KRAS mutation, only one showed positivity for c-kit immunostaining, and only two cases showed positivity for EGFR immunostaining. The case that showed both KRAS and BRAF mutations was weakly positive for EGFR, VEGF, and c-kit. The secondary patterns observed in cases with KRAS mutations were papillary, acinar, and lepidic patterns. A secondary papillary pattern correlated with smoking (P = 0.002), psammoma bodies (P = 0.002), and perineural invasion (P = 0.001). Immunohistochemically, EGFR positivity correlated with perineural invasion (P = 0.004). There was no significant correlation between mutation, morphological, and clinical features. It was very difficult to reach targeted therapy between January 2000 and December 2010, so only one patient with EGFR mutation in exon 19 was treated with EGFR tyrosine kinase inhibitor and survived 50 months. Others were treated with platinum-based chemotherapy, and the mean survival time of all these patients was 30.5 months. The overall survival of the patient that showed both KRAS and BRAF mutations was 14 months.
Discussion
Although micropapillary carcinoma had previously been reported in several other organs, including the breast, ovary, and urinary bladder, the first subtype of pulmonary adenocarcinoma was described by Amin et al. in 2002 (13) . Pulmonary micropapillary adenocarcinoma is associated with a high risk of lymph node metastasis and a poor prognosis, in a similar manner to other anatomical locations (14, 15) . This subtype was not defined in the 1999 and 2004 World Health Organization (WHO)/ International Association for the Study of Lung Cancer Classifications (16) . However, micropapillary lung adenocarcinoma was classified as micropapillary dominant in the proposed new lung adenocarcinoma classification of resected tumors, in which the use of comprehensive histological subtyping to semiquantitatively assess histologic patterns in 5% increments, choosing a single (8) . In the present study, we used the most recent adenocarcinoma classification to identify females with micropapillary dominant adenocarcinoma (Table 5 ). Our patients were younger than those studied by Achcar et al. (6) , and we used a larger patient sample. Only two patients had a history of smoking. Although we found that the most common secondary pattern in our cases was the papillary pattern, the lepidic pattern was the most frequently observed secondary pattern found in the study by Achcar et al. We found that a secondary papillary pattern correlated with smoking (P = 0.002), psammoma bodies (P = 0.002), and perineural invasion (P = 0.001).
Driver genes are those that encode the signaling proteins that are critical for cellular proliferation and survival. Lung adenocarcinoma driver genes include EGFR, KRAS, BRAF, PIK3CA, and EML-ALK. Initiation and maintenance of malignancy are the result of mutations of these genes (18) . Different studies of driver gene mutations in nonsmall-cell lung carcinoma (NSCLC) have led to varying results because of differences in patient ethnicity or clinical information. EGFR and KRAS mutations were observed in 10%-30% of cases, with a higher frequency of EGFR mutations being found in Asians, in people who had no history of smoking, and in nonmucinous tumors (5) . However, it has been found that the level of KRAS mutation is associated with smoking, being non-Asian, and invasive mucinous adenocarcinoma (19) . A BRAF mutation rate of 1.9% was reported in nonsmokers with adenocarcinoma (18) . With regard to the correlation between histological subtype and driver mutations, Li et al. found a significantly higher frequency of EGFR mutations in micropapillary dominant adenocarcinoma (11 of 13 cases, 84.6%), while no other driver mutations were found in this subtype (10). Achcar et al. reported an EGFR mutation rate in 10%, a KRAS mutation rate in 23%, and a BRAF mutation rate in 5.5% of cases (6) . In our study, EGFR, KRAS, and BRAF mutation rates were 40%, 20%, and 6.6%, respectively, and the frequency of EGFR mutation was higher than that observed by Achcar et al. These results may be related to the sex of the patient. However, recent studies have shown that the EGFR mutation frequency of the micropapillary dominant subtype is higher that of other subtypes (20, 21) . The types of EGFR mutations reported in pulmonary adenocarcinoma are multiple deletions in exon 19 in 45% of cases, missense point mutations in exon 21 in 40% of cases, and missense or insertion mutations in exons 18-21 in 15% of cases (22) . In our study, EGFR mutation in exon 19 was most frequently observed (5 cases, 83.3%), and EGFR immunostaining was not correlated with EGFR mutation. KRAS mutation is found in approximately 30% of adenocarcinomas, and single amino acid substitutions in codons 12, 13, and 61 are the most frequently observed KRAS mutations in NSCLC. Negative predictive markers of KRAS mutation are most commonly found in the white population and in smokers. (18), while we identified one case that showed both KRAS and BRAF mutations. This is different from mutually exclusive KRAS and EGFR mutations.
Our study was associated with a higher rate of EGFR mutation than previous studies. When a cancer comprises more than 5% MMP, the prognosis is poor, even with regards to pathological stage I disease. However, patients with EGFR-mutated adenocarcinomas had improved survival rates. This dilemma was explained via the strong positivity of VEGF; angiogenesis is very important for tumor progression. Previous studies have shown that strong VEGF immunostaining is correlated with postoperative relapse and survival in NSCLC (23) .
Kit (CD117), the product in the protooncogene c-kit, is a tyrosine kinase transmembrane receptor that regulates the development and growth of some human cell types. Inhibitors of c-kit have been used in the treatment of gastrointestinal stromal tumors. In our study, c-kit positivity was observed in three cases with EGFR mutation. Data on c-kit immunostaining in NSCLC is limited, but Butnor et al. detected c-kit positivity in 17% of adenocarcinomas (24) , while 46.6% of our cases were positive for c-kit.
In this study EGFR mutation occurred at a higher incidence in micropapillary predominant invasive adenocarcinoma than has previously been found in conventional lung adenocarcinomas. Our data highlight the national mutation profile of micropapillary predominant invasive lung adenocarcinoma, which is associated with a poor prognosis and a high grade. We must ascertain the factors that influence targeted mutation with further studies.
